Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Reaches Deal for $1.5B Credit Facility

NEW YORK – PerkinElmer said after the close of the market on Wednesday that it has entered into an agreement for a new $1.5 billion revolving credit facility.

The agreement provides for the unsecured revolving credit facility through Aug. 24, 2026, and replaces an unsecured revolving credit agreement dated Sept. 17, 2019, which provided for a $1 billion unsecured revolving credit facility.

Bank of America was the administrative agent, swing line lender, and line of credit issuer on the transaction. Other lenders included Goldman Sachs Bank USA, JP Morgan Chase Bank, and Wells Fargo Bank NA.

Earlier this month, Waltham, Massachusetts-based PerkinElmer reached an agreement for a $500 million credit facility to help pay for its $5.25 billion acquisition of BioLegend.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.